Cargando…

The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer

BACKGROUND: A fraction of sporadic breast cancers has low BRCA1 expression. BRCA1 mutation carriers are more likely to achieve a pathological complete response with DNA-damage-based chemotherapy compared to non-mutation carriers. Furthermore, sporadic ovarian cancer patients with low levels of BRCA1...

Descripción completa

Detalles Bibliográficos
Autores principales: Margeli, Mireia, Cirauqui, Beatriz, Castella, Eva, Tapia, Gustavo, Costa, Carlota, Gimenez-Capitan, Ana, Barnadas, Agusti, Ronco, Maria Sanchez, Benlloch, Susana, Taron, Miquel, Rosell, Rafael
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831058/
https://www.ncbi.nlm.nih.gov/pubmed/20209131
http://dx.doi.org/10.1371/journal.pone.0009499
_version_ 1782178210894577664
author Margeli, Mireia
Cirauqui, Beatriz
Castella, Eva
Tapia, Gustavo
Costa, Carlota
Gimenez-Capitan, Ana
Barnadas, Agusti
Ronco, Maria Sanchez
Benlloch, Susana
Taron, Miquel
Rosell, Rafael
author_facet Margeli, Mireia
Cirauqui, Beatriz
Castella, Eva
Tapia, Gustavo
Costa, Carlota
Gimenez-Capitan, Ana
Barnadas, Agusti
Ronco, Maria Sanchez
Benlloch, Susana
Taron, Miquel
Rosell, Rafael
author_sort Margeli, Mireia
collection PubMed
description BACKGROUND: A fraction of sporadic breast cancers has low BRCA1 expression. BRCA1 mutation carriers are more likely to achieve a pathological complete response with DNA-damage-based chemotherapy compared to non-mutation carriers. Furthermore, sporadic ovarian cancer patients with low levels of BRCA1 mRNA have longer survival following platinum-based chemotherapy than patients with high levels of BRCA1 mRNA. METHODOLOGY/PRINCIPAL FINDINGS: Tumor biopsies were obtained from 86 breast cancer patients who were candidates for neoadjuvant chemotherapy, treated with four cycles of neoadjuvant fluorouracil, epirubicin and cyclophosphamide. Estrogen receptor (ER), progesterone receptor (PR), HER2, cytokeratin 5/6 and vimentin were examined by tissue microarray. HER2 were also assessed by chromogenic in situ hybridization, and BRCA1 mRNA was analyzed in a subset of 41 patients for whom sufficient tumor tissue was available by real-time quantitative PCR. Median time to progression was 42 months and overall survival was 55 months. In the multivariate analysis for time to progression and overall survival for 41 patients in whom BRCA1 could be assessed, low levels of BRCA1 mRNA, positive PR and negative lymph node involvement predicted a significantly lower risk of relapse, low levels of BRCA1 mRNA and positive PR were the only variables associated with significantly longer survival. CONCLUSIONS/SIGNIFICANCE: We provide evidence for a major role for BRCA1 mRNA expression as a marker of time to progression and overall survival in sporadic breast cancers treated with anthracycline-based chemotherapy. These findings can be useful for customizing chemotherapy.
format Text
id pubmed-2831058
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-28310582010-03-06 The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer Margeli, Mireia Cirauqui, Beatriz Castella, Eva Tapia, Gustavo Costa, Carlota Gimenez-Capitan, Ana Barnadas, Agusti Ronco, Maria Sanchez Benlloch, Susana Taron, Miquel Rosell, Rafael PLoS One Research Article BACKGROUND: A fraction of sporadic breast cancers has low BRCA1 expression. BRCA1 mutation carriers are more likely to achieve a pathological complete response with DNA-damage-based chemotherapy compared to non-mutation carriers. Furthermore, sporadic ovarian cancer patients with low levels of BRCA1 mRNA have longer survival following platinum-based chemotherapy than patients with high levels of BRCA1 mRNA. METHODOLOGY/PRINCIPAL FINDINGS: Tumor biopsies were obtained from 86 breast cancer patients who were candidates for neoadjuvant chemotherapy, treated with four cycles of neoadjuvant fluorouracil, epirubicin and cyclophosphamide. Estrogen receptor (ER), progesterone receptor (PR), HER2, cytokeratin 5/6 and vimentin were examined by tissue microarray. HER2 were also assessed by chromogenic in situ hybridization, and BRCA1 mRNA was analyzed in a subset of 41 patients for whom sufficient tumor tissue was available by real-time quantitative PCR. Median time to progression was 42 months and overall survival was 55 months. In the multivariate analysis for time to progression and overall survival for 41 patients in whom BRCA1 could be assessed, low levels of BRCA1 mRNA, positive PR and negative lymph node involvement predicted a significantly lower risk of relapse, low levels of BRCA1 mRNA and positive PR were the only variables associated with significantly longer survival. CONCLUSIONS/SIGNIFICANCE: We provide evidence for a major role for BRCA1 mRNA expression as a marker of time to progression and overall survival in sporadic breast cancers treated with anthracycline-based chemotherapy. These findings can be useful for customizing chemotherapy. Public Library of Science 2010-03-03 /pmc/articles/PMC2831058/ /pubmed/20209131 http://dx.doi.org/10.1371/journal.pone.0009499 Text en Margeli et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Margeli, Mireia
Cirauqui, Beatriz
Castella, Eva
Tapia, Gustavo
Costa, Carlota
Gimenez-Capitan, Ana
Barnadas, Agusti
Ronco, Maria Sanchez
Benlloch, Susana
Taron, Miquel
Rosell, Rafael
The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer
title The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer
title_full The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer
title_fullStr The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer
title_full_unstemmed The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer
title_short The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer
title_sort prognostic value of brca1 mrna expression levels following neoadjuvant chemotherapy in breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831058/
https://www.ncbi.nlm.nih.gov/pubmed/20209131
http://dx.doi.org/10.1371/journal.pone.0009499
work_keys_str_mv AT margelimireia theprognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT cirauquibeatriz theprognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT castellaeva theprognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT tapiagustavo theprognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT costacarlota theprognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT gimenezcapitanana theprognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT barnadasagusti theprognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT roncomariasanchez theprognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT benllochsusana theprognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT taronmiquel theprognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT rosellrafael theprognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT margelimireia prognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT cirauquibeatriz prognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT castellaeva prognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT tapiagustavo prognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT costacarlota prognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT gimenezcapitanana prognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT barnadasagusti prognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT roncomariasanchez prognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT benllochsusana prognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT taronmiquel prognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer
AT rosellrafael prognosticvalueofbrca1mrnaexpressionlevelsfollowingneoadjuvantchemotherapyinbreastcancer